Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.